Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Image:Veltassa enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. Photo: courtesy of Nordwest-Krankenhaus Sanderbusch / FreeImages.